share_log

Invivyd | 8-K: Current report

Invivyd | 8-K: Current report

Invivyd | 8-K：重大事件
SEC announcement ·  04/12 19:41
牛牛AI助理已提取核心訊息
Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic...Show More
Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic guidance. In addition, the Board has reduced its size from nine to eight members. The company has also issued a press release on April 12, 2024, detailing these management changes and highlighting the company's focus on delivering monoclonal antibody therapies for the prevention of COVID-19. Invivyd's lead product, PEMGARDA™, has shown promise in clinical trials and has been authorized for emergency use by the U.S. FDA for certain immunocompromised individuals.
生物製藥公司Invivyd, Inc. 宣佈其執行領導層發生重大變動。Invivyd首席執行官大衛·赫林已辭去公司董事會成員的職務，自2024年4月11日起生效。他在公司的工作將於2024年5月11日正式結束。董事會正在積極尋找永久替代者。同時，自2022年12月起在Invivyd擔任首席運營官兼首席商務官的傑里米·高勒被任命爲臨時首席執行官。高勒的豐富經驗包括在諾華旗下的山德士和Emergent Biosolutions擔任過職務。在擔任臨時首席執行官期間，他將繼續履行先前的職務，並將與執行委員會合作提供戰略指導。此外，該委員會已將其成員人數從九名減少到八名。該公司還於2024年4月12日發佈了一份新聞稿，詳細介紹了這些管理層變動，並強調了該公司專注於提供預防 COVID-19 的單克隆抗體療法。Invivyd的主要產品PEMGARDA™ 已在臨床試驗中顯示出希望，並已獲得美國食品藥品管理局的批准，可供某些免疫功能低下的人緊急使用。
生物製藥公司Invivyd, Inc. 宣佈其執行領導層發生重大變動。Invivyd首席執行官大衛·赫林已辭去公司董事會成員的職務，自2024年4月11日起生效。他在公司的工作將於2024年5月11日正式結束。董事會正在積極尋找永久替代者。同時，自2022年12月起在Invivyd擔任首席運營官兼首席商務官的傑里米·高勒被任命爲臨時首席執行官。高勒的豐富經驗包括在諾華旗下的山德士和Emergent Biosolutions擔任過職務。在擔任臨時首席執行官期間，他將繼續履行先前的職務，並將與執行委員會合作提供戰略指導。此外，該委員會已將其成員人數從九名減少到八名。該公司還於2024年4月12日發佈了一份新聞稿，詳細介紹了這些管理層變動，並強調了該公司專注於提供預防 COVID-19 的單克隆抗體療法。Invivyd的主要產品PEMGARDA™ 已在臨床試驗中顯示出希望，並已獲得美國食品藥品管理局的批准，可供某些免疫功能低下的人緊急使用。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。